Myeloma Crowd Radio: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma

A new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cells or NK cells) to kill myeloma. Learn more about this emerging therapy from Dr. Shaji Kumar on this fascinating program. 

Thanks to our episode sponsor, Takeda Oncology